Publication date: Jul 05, 2025
“How effective was the nasal vaccine?The clinical trial included 72 people who received vaccinations, with ages ranging from 12 to 53. One group received a low dose of the vaccine, which served as a control group. Now, encouraging results are in from the first human clinical trial to be conducted in the United States of a nasal COVID vaccine. A nasal vaccine could prove both more effective medically and more tolerable for young children and adults who may fear needles. However, definitive proof of efficacy will require larger trials designed specifically for this purpose. What’s next?By design, a phase 1 clinical trial involves low numbers of participants. “A nasal vaccine has the potential to block SARS-CoV-2 at its mucosal entry site and to reduce transmission of the virus to others. This has required adjusting the vaccine and suggests that annual re-vaccination may be needed to prevent another pandemic.
| Concepts | Keywords |
|---|---|
| Deadliest | Cincinnati |
| June | Clinical |
| Vaccine | Covid |
| Wealthy | Deaths |
| Dose | |
| Group | |
| Infection | |
| Larger | |
| Nasal | |
| Pandemic | |
| Trial | |
| Trials | |
| Vaccine | |
| Vaccines | |
| Virus |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | infection |
| disease | MESH | COVID-19 pandemic |
| disease | IDO | site |